Rice Business Plan Competition

FOR IMMEDIATE RELEASE

April 15, 2025

Ann Arbor, MI —

We’re excited to share that Intero Biosystems was awarded first place and more than $900,000 in investment prizes at the 2025 Rice Business Plan Competition—the world’s largest and richest student startup competition.

Out of 42 teams from around the world, Intero placed among the top finalists and received funding from multiple investors, including Goose Capital, Houston Angel Network, nCourage Investment Group, and more. This incredible recognition is a testament to the growing momentum around human organoid models as the future of preclinical testing, and the rigorous science behind GastroScreen.

We’re deeply grateful to the Rice Alliance for Technology and Entrepreneurship, the judges, mentors, and investors who believed in our vision—and to our amazing team who made this possible.

To read more about the competition, CLICK HERE.

 . . .

ABOUT INTERO BIOSYSTEMS
Intero Biosystems is a biotechnology company developing advanced adult human stem cell–derived intestinal organoid platforms for drug discovery and development. Founded in 2024 as a spin-out from Dr. Jason Spence’s lab at the University of Michigan, Intero’s mission is to improve the predictability and efficiency of preclinical testing—failing ineffective drug candidates faster and helping identify safer, more effective treatments for patients in need.

MEDIA CONTACT
Charlie Childs, Ph.D.
CEO, Intero Biosystems
charlie@interobiosystems.com
www.interobiosystems.com